Peer-reviewed literature on the CyberKnife® System is accumulating rapidly. Below is a list of papers published in respected medical journals describing CyberKnife treatment throughout the body, along with a brief summary for each. Click on the links to see each paper’s full reference and abstract located online (most on PubMed, a medical research search site maintained by the U.S. National Library of Medicine and the National Institutes of Health).

Pancreas

Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Koong et al. 2004. Stanford University researchers treated patients with locally advanced pancreatic cancer using the CyberKnife System.  They found it was feasible to achieve local control without significant acute gastrointestinal toxicity using a dose of 25 Gy.
Click here for full abstract

Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Koong et al. 2005. Stanford University researchers found that concurrent IMRT and 5-FU followed by treatment with the CyberKnife System on patients with locally advanced pancreatic cancer results in excellent local control. Overall survival was not affected, and the combined treatment caused more toxicity than radiosurgery alone.
Click here for full abstract

Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Schellenberg et al. 2008. Stanford University researchers found that combining gemcitabine chemotherapy with CyberKnife System treatment resulted in good local control, but that a significant rate of duodenal ulcers occurred.
Click here for full abstract